S-1: Alzamend Neuro Files for Resale of 125 Million Shares Amid Nasdaq Listing Concerns

Alzamend Neuro is registering for resale up to 125 million shares of common stock by Orchid Finance LLC, while also addressing ongoing Nasdaq listing compliance issues.

Summary

• Alzamend Neuro, Inc. has filed a registration statement for the resale of up to 125,000,000 shares of its common stock by Orchid Finance LLC.
• These shares include 105,000,000 shares issuable upon conversion of Series A Convertible Preferred Stock and 20,000,000 shares issuable upon exercise of warrants.
• The company will not receive any proceeds from the sale of these shares by the Selling Stockholder, except if the Selling Stockholder exercises its Warrants.
• Alzamend Neuro is currently addressing Nasdaq listing deficiencies related to minimum Market Value of Listed Securities (MVLS) and minimum bid price.
• The company received an extension until September 23, 2024, to comply with the MVLS rule and until July 30, 2024, to regain compliance with the minimum bid price rule.
• The company's lead product candidate, AL001, is in clinical development for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD.
• ALZN002, an immunotherapy vaccine, is in Phase I/IIA clinical trial for mild to moderate dementia of the Alzheimer's type.
• The company's ability to continue its operations is dependent on raising additional capital.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as ongoing clinical trials and FDA approvals for IND applications, the company faces significant challenges including Nasdaq listing deficiencies, reliance on additional funding, and potential dilution of stock. The overall sentiment is cautiously negative due to the financial and regulatory hurdles the company must overcome.

Positives

• The company has received 'study may proceed' letters from the FDA for Investigational New Drug (IND) applications for AL001 for bipolar disorder, major depressive disorder, and PTSD.
• The company has identified a maximum tolerated dose (MTD) for AL001, designed to be unlikely to require lithium therapeutic drug monitoring (TDM).
• The FDA agreed to allow Alzamend to submit an IND to conduct a combined Phase I/II study for ALZN002.
• The company has secured a commitment from the Selling Stockholder to purchase up to $25 million of Preferred Shares, subject to the company achieving certain milestones.

Negatives

• The company is not in compliance with Nasdaq continued listing requirements.
• The company's Common Stock could be delisted if it fails to comply with Nasdaq listing standards.
• The company's ability to access the full amount available under the Purchase Agreement is contingent on meeting certain milestones, which are not guaranteed.
• The Preferred Shares are convertible into Common Stock at a discount to the market price, which would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders.
• The company may not receive any additional funds upon the exercise of the Warrants.
• The company has a history of significant losses and anticipates continuing to incur significant losses for the foreseeable future.

Risks

• The company's need for substantial additional funding to finance operations and complete development of AL001 and ALZN002.
• The company's ability to effectively execute its business strategy.
• The company's ability to manage its expansion, growth, and operating expenses.
• The company's ability to compete and succeed in a highly competitive and evolving industry.
• The company's ability to protect its intellectual property.
• The risk that the development of AL001 and ALZN002 may not lead to marketable products.
• The risk that the company's product candidates may not qualify for expedited development.
• The company's reliance on licenses from a third party regarding its rights and development of AL001 and ALZN002.

Future Outlook

The company intends to develop and commercialize therapeutics that are better than existing treatments and have the potential to significantly improve the lives of individuals afflicted by Alzheimer's, BD, MDD, and PTSD. The company plans to initiate two safety and efficacy clinical trials in subjects with mild to moderate dementia of the Alzheimer's type. Additionally, the company is investigating the potential of AL001 for patients suffering from BD, MDD, and PTSD, and intends to initiate clinical trials at the MTD to determine relative increased lithium levels in the brain compared to a marketed lithium salt for BD, MDD and PTSD.

Industry Context

The company operates in the pharmaceutical industry, specifically focusing on developing treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder. The company's approach to combat Alzheimer's through immunotherapy is a novel approach. The company's lead product candidate, AL001, is an ionic cocrystal of lithium for the treatment of Alzheimer's, BD, MDD and PTSD. Lithium has been marketed for more than 35 years and human toxicology regarding lithium use has been well characterized, potentially mitigating the regulatory burden for safety data.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• However, the document does mention that Lithium was the first mood stabilizer approved by the U.S. Food and Drug Administration (FDA) and is still a first-line treatment option (considered the gold standard) but is underutilized perhaps because of the need for TDM.
• The document also mentions that compared to passive immunization treatment approaches that use foreign blood products (such as monoclonal antibodies), active immunization with ALZN002 is anticipated to offer a more robust and long-lasting effect on the clearance of amyloid.

Related Party Transactions

• The Company agreed to pay Ault Lending, LLC, a related party, an origination fee of five percent (5%) of the total gross proceeds received by the Company from the Selling Stockholder upon each purchase of Preferred Shares.
• The Company has also agreed to pay the Selling Stockholder a fee of $100,000 upon each of the First Tranche, the Fourth Tranche and the third, eighth and thirteenth closings constituting parts of the Final Tranche.

Stakeholder Impact

• Shareholders face potential dilution from the conversion of Preferred Shares and exercise of Warrants.
• Employees' job security is tied to the company's ability to secure funding and maintain Nasdaq listing.
• Customers (patients) may benefit from successful development of new treatments for Alzheimer's, BD, MDD, and PTSD.
• Suppliers and creditors face increased risk due to the company's financial instability and need for additional funding.

Next Steps

• The company intends to actively monitor the closing bid price of its Common Stock between now and July 30, 2024 and may, if appropriate, evaluate available options to resolve the deficiency and regain compliance with the Minimum Bid Price requirement.
• The company intends to initiate clinical trials at the MTD to determine relative increased lithium levels in the brain compared to a marketed lithium salt for BD, MDD and PTSD.
• The company anticipates beginning Phase II studies for the additional indications after it has obtained the necessary financing for the trials and payment to Phase IIA MAD study vendor for the final reports of that study.

Key Dates

Keywords

Alzamend Neuro, Common Stock, Preferred Shares, Warrants, Nasdaq, AL001, ALZN002, Alzheimer's, Bipolar Disorder, Registration Statement, Orchid Finance LLC, Clinical Trials, FDA, Listing Deficiency